Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

New generations of targeted therapies fighting the resistance in solid tumors

Barthélémy, Philippea,b; Aftimos, Philippea; Awada, Ahmada

doi: 10.1097/CCO.0000000000000175
INNOVATIVE EARLY CLINICAL TRIALS METHODOLOGY AND NEW THERAPEUTICS IN CANCER: Edited by Ahmad Awada
Buy

Purpose of review The identification of molecular alterations that drive tumor growth and spread of solid tumors has led to the development of multiple targeted therapies considered as first-generation agents that have improved clinical benefit. However, tumor cells are able to rapidly develop resistance to these agents. The growing understanding of the biology of the resistance mechanisms has spurred ongoing development of second-generation and third-generation targeted therapies aiming at new strategies to overcome resistance.

Recent findings Several generations of targeted therapies have been developed in order to prevent, delay or overcome tumor resistance. Some agents have already been approved, and others are currently under active clinical investigation in several cancer subtypes, including breast cancer, nonsmall cell lung cancer, head and neck squamous cell cancer and colorectal cancer.

Summary In the present review, we will discuss in solid tumors, the recent development of next generation anticancer-targeted therapies and new strategies including combination agents currently under active clinical investigation.

aMedical Oncology Clinic, Institut Jules Bordet, Université libre de Bruxelles, Brussels, Belgium

bDépartement d’Oncologie médicale et d’hématologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France

Correspondence to Philippe Barthélémy, MD, Département d’Oncologie médicale et d’hématologie, Hôpitaux Universitaires de Strasbourg, 1 place de l’Hôpital, 67091 Strasbourg, France. Tel: +33 3 88 11 58 77; e-mail: philippe.barthelemy@chru-strasbourg.fr

Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.